These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 2309313)

  • 1. Improved survival in marrow recipients above 30 years of age with better prevention of graft-versus-host disease.
    Aschan J; Ringdén O; Tollemar J; Ljungman P; Lönnqvist B; Pihlstedt P; Markling L; Sundberg B
    Transplant Proc; 1990 Feb; 22(1):195-7. PubMed ID: 2309313
    [No Abstract]   [Full Text] [Related]  

  • 2. Omission of day 11 methotrexate does not appear to influence the incidence of moderate to severe acute graft-versus-host disease, chronic graft-versus-host disease, relapse rate or survival after HLA-identical sibling bone marrow transplantation.
    Atkinson K; Downs K
    Bone Marrow Transplant; 1995 Dec; 16(6):755-8. PubMed ID: 8750265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors for acute graft-versus-host disease in 325 consecutive bone marrow recipients.
    Hägglund H; Boström L; Ringdén O; Nilsson B; Remberger M
    Transplant Proc; 1994 Jun; 26(3):1821-2. PubMed ID: 8030154
    [No Abstract]   [Full Text] [Related]  

  • 4. Prognostic factors for long-term survival in leukemic marrow recipients with special emphasis on age and prophylaxis for graft-versus-host disease.
    Aschan J; Ringdén O
    Clin Transplant; 1994 Jun; 8(3 Pt 1):258-70. PubMed ID: 8061365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone marrow transplantation from genetically HLA-nonidentical donors in children with fatal inherited disorders excluding severe combined immunodeficiencies: use of two monoclonal antibodies to prevent graft rejection.
    Jabado N; Le Deist F; Cant A; De Graeff-Meeders ER; Fasth A; Morgan G; Vellodi A; Hale G; Bujan W; Thomas C; Cavazzana-Calvo M; Wijdenes J; Fischer A
    Pediatrics; 1996 Sep; 98(3 Pt 1):420-8. PubMed ID: 8784367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
    Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multicenter, randomized, double-blind comparison of different doses of intravenous immunoglobulin for prevention of graft-versus-host disease and infection after allogeneic bone marrow transplantation.
    Winston DJ; Antin JH; Wolff SN; Bierer BE; Small T; Miller KB; Linker C; Kaizer H; Lazarus HM; Petersen FB; Cowan MJ; Ho WG; Wingard JR; Schiller GJ; Territo MC; Jiao J; Petrarca MA; Tonetta SA
    Bone Marrow Transplant; 2001 Jul; 28(2):187-96. PubMed ID: 11509937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of AB0-blood group incompatibility on the outcome of recipients of bone marrow transplants from unrelated donors in the Japan Marrow Donor Program.
    Kimura F; Sato K; Kobayashi S; Ikeda T; Sao H; Okamoto S; Miyamura K; Mori S; Akiyama H; Hirokawa M; Ohto H; Ashida H; Motoyoshi K;
    Haematologica; 2008 Nov; 93(11):1686-93. PubMed ID: 18835834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lymphocyte depletion in bone marrow transplantation: will modulation of graft-versus-host disease prove to be superior to prevention?
    Noga SJ; Hess AD
    Semin Oncol; 1993 Oct; 20(5 Suppl 6):28-33. PubMed ID: 8211214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of graft-versus-host disease after bone marrow and small bowel transplantation by ultraviolet B modulation of bone marrow cells.
    Chowdhury NC; Jin MX; Hardy MA; Oluwole SF
    Transplant Proc; 1993 Feb; 25(1 Pt 1):475-6. PubMed ID: 8438384
    [No Abstract]   [Full Text] [Related]  

  • 11. Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis.
    Carlens S; Ringdén O; Remberger M; Lönnqvist B; Hägglund H; Klaesson S; Mattsson J; Svahn BM; Winiarski J; Ljungman P; Aschan J
    Bone Marrow Transplant; 1998 Oct; 22(8):755-61. PubMed ID: 9827972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
    Asai O; Longo DL; Tian ZG; Hornung RL; Taub DD; Ruscetti FW; Murphy WJ
    J Clin Invest; 1998 May; 101(9):1835-42. PubMed ID: 9576746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-2 for prevention of graft-versus-host disease after haploidentical marrow transplantation.
    Przepiorka D; Ippoliti C; Koberda J; Chan KW; Khouri IF; Fischer HE; Huh YO; Escudier SM; Seong D; Davis M
    Transplantation; 1994 Oct; 58(7):858-60. PubMed ID: 7940725
    [No Abstract]   [Full Text] [Related]  

  • 14. Ultraviolet irradiation for the prevention of graft-versus-host disease and graft rejection in bone marrow transplantation.
    Hudson JG; Lawler M; Pamphilon DH
    Bone Marrow Transplant; 1994 Oct; 14(4):511-6. PubMed ID: 7858525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time of onset, viral load, relapse, and duration of active cytomegalovirus infection in bone marrow transplant outcomes.
    Habib K; Lamia T; Amel L; Abdelrahmen A; Saloua L; Hana E; Amine S; Bechir Z; Tarek BO; Assia BH
    Exp Clin Transplant; 2008 Mar; 6(1):67-73. PubMed ID: 18405248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simultaneous protection against allograft rejection and graft-versus-host disease after total lymphoid irradiation: role of natural killer T cells.
    Liu YP; Li Z; Nador RG; Strober S
    Transplantation; 2008 Feb; 85(4):607-14. PubMed ID: 18347541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results of allogeneic bone marrow transplantation for acute leukemia have improved in Europe with time--a report of the acute leukemia working party of the European group for blood and marrow transplantation (EBMT).
    Frassoni F; Labopin M; Gluckman E; Prentice HG; Vernant JP; Zwaan F; Granena A; Gahrton G; De Witte T; Gratwohl A; Reiffers J; Gorin NC
    Bone Marrow Transplant; 1996 Jan; 17(1):13-8. PubMed ID: 8673048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FK 506-based immunosuppression for prevention of graft versus host disease after unrelated donor marrow transplantation.
    Fay JW; Nash RA; Wingard JR; Przepiorka D; Collins RH; Anasetti C; Devine SM; Piñeiro LA; Storb RF; Aro RM
    Transplant Proc; 1995 Feb; 27(1):1374. PubMed ID: 7533383
    [No Abstract]   [Full Text] [Related]  

  • 19. Prevention of graft-versus-host disease on an individual basis.
    Aschan J; Ringdén O; Andström E; Ljungman P; Remberger M
    Transplant Proc; 1994 Jun; 26(3):1823-4. PubMed ID: 8030155
    [No Abstract]   [Full Text] [Related]  

  • 20. LF 08-0299 protects murine recipients of minor antigen disparate donor bone marrow from lethal graft-versus-host disease.
    Bruley-Rosset M; Churaqui E; Annat J; Dutartre P
    Transplant Proc; 1996 Dec; 28(6):3114-6. PubMed ID: 8962208
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.